These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 19003578)

  • 1. Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis.
    Ignatenko NA; Besselsen DG; Stringer DE; Blohm-Mangone KA; Cui H; Gerner EW
    Nutr Cancer; 2008; 60 Suppl 1():30-5. PubMed ID: 19003578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
    Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
    BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyamines as mediators of APC-dependent intestinal carcinogenesis and cancer chemoprevention.
    Rial NS; Meyskens FL; Gerner EW
    Essays Biochem; 2009 Nov; 46():111-24. PubMed ID: 20095973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis.
    Bowen CM; Walter L; Borras E; Wu W; Ozcan Z; Chang K; Bommi PV; Taggart MW; Thirumurthi S; Lynch PM; Reyes-Uribe L; Scheet PA; Sinha KM; Vilar E
    Cancer Prev Res (Phila); 2021 Sep; 14(9):851-862. PubMed ID: 34266857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos.
    Jacoby RF; Cole CE; Tutsch K; Newton MA; Kelloff G; Hawk ET; Lubet RA
    Cancer Res; 2000 Apr; 60(7):1864-70. PubMed ID: 10766173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dietary putrescine reduces the intestinal anticarcinogenic activity of sulindac in a murine model of familial adenomatous polyposis.
    Ignatenko NA; Besselsen DG; Roy UK; Stringer DE; Blohm-Mangone KA; Padilla-Torres JL; Guillen-R JM; Gerner EW
    Nutr Cancer; 2006; 56(2):172-81. PubMed ID: 17474863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoprevention with special reference to inherited colorectal cancer.
    Lynch PM
    Fam Cancer; 2008; 7(1):59-64. PubMed ID: 17680350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of dietary amino acids and polyamines on intestinal carcinogenesis and chemoprevention in mouse models.
    Gerner EW
    Biochem Soc Trans; 2007 Apr; 35(Pt 2):322-5. PubMed ID: 17371270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor.
    Oshima M; Murai N; Kargman S; Arguello M; Luk P; Kwong E; Taketo MM; Evans JF
    Cancer Res; 2001 Feb; 61(4):1733-40. PubMed ID: 11245490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. APC-dependent changes in expression of genes influencing polyamine metabolism, and consequences for gastrointestinal carcinogenesis, in the Min mouse.
    Erdman SH; Ignatenko NA; Powell MB; Blohm-Mangone KA; Holubec H; Guillén-Rodriguez JM; Gerner EW
    Carcinogenesis; 1999 Sep; 20(9):1709-13. PubMed ID: 10469614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis.
    Lynch PM; Burke CA; Phillips R; Morris JS; Slack R; Wang X; Liu J; Patterson S; Sinicrope FA; Rodriguez-Bigas MA; Half E; Bulow S; Latchford A; Clark S; Ross WA; Malone B; Hasson H; Richmond E; Hawk E
    Gut; 2016 Feb; 65(2):286-95. PubMed ID: 25792707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of Erlotinib Plus Sulindac Dosing Regimens for Intestinal Cancer Prevention in an Apc-Mutant Model of Familial Adenomatous Polyposis (FAP).
    Ulusan AM; Rajendran P; Dashwood WM; Yavuz OF; Kapoor S; Gustafson TA; Savage MI; Brown PH; Sei S; Mohammed A; Vilar E; Dashwood RH
    Cancer Prev Res (Phila); 2021 Mar; 14(3):325-336. PubMed ID: 33277315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostanoids, ornithine decarboxylase, and polyamines in primary chemoprevention of familial adenomatous polyposis.
    Giardiello FM; Casero RA; Hamilton SR; Hylind LM; Trimbath JD; Geiman DE; Judge KR; Hubbard W; Offerhaus GJ; Yang VW
    Gastroenterology; 2004 Feb; 126(2):425-31. PubMed ID: 14762779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoprevention in familial adenomatous polyposis: past, present and future.
    Kemp Bohan PM; Mankaney G; Vreeland TJ; Chick RC; Hale DF; Cindass JL; Hickerson AT; Ensley DC; Sohn V; Clifton GT; Peoples GE; Burke CA
    Fam Cancer; 2021 Jan; 20(1):23-33. PubMed ID: 32507936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Celecoxib: new indication. Colorectal cancer: no preventive benefit.
    Prescrire Int; 2006 Feb; 15(81):13-5. PubMed ID: 16548099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouse.
    Ritland SR; Leighton JA; Hirsch RE; Morrow JD; Weaver AL; Gendler SJ
    Clin Cancer Res; 1999 Apr; 5(4):855-63. PubMed ID: 10213222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.
    Sinicrope FA; Half E; Morris JS; Lynch PM; Morrow JD; Levin B; Hawk ET; Cohen DS; Ayers GD; Stephens LC;
    Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):920-7. PubMed ID: 15184247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous Polyposis: A Randomized Clinical Trial.
    Samadder NJ; Neklason DW; Boucher KM; Byrne KR; Kanth P; Samowitz W; Jones D; Tavtigian SV; Done MW; Berry T; Jasperson K; Pappas L; Smith L; Sample D; Davis R; Topham MK; Lynch P; Strait E; McKinnon W; Burt RW; Kuwada SK
    JAMA; 2016 Mar 22-29; 315(12):1266-75. PubMed ID: 27002448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoprevention in familial adenomatous polyposis.
    Kim B; Giardiello FM
    Best Pract Res Clin Gastroenterol; 2011 Aug; 25(4-5):607-22. PubMed ID: 22122775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
    Jacoby RF; Seibert K; Cole CE; Kelloff G; Lubet RA
    Cancer Res; 2000 Sep; 60(18):5040-4. PubMed ID: 11016626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.